United Kingdom· GB-APID-34486911000001104
Parsabiv 5mg/1ml solution for injection vials
A etelcalcetide product containing etelcalcetide, registered in United Kingdom by Amgen Ltd. The same ATC class is registered in 14 of our 19 countries.
Checked against NHS dm+d (United Kingdom) on
Informational only — not a medical device.
Where it is registered
Etelcalcetide is registered in 14 of 19 countries.
Countries holding a registration under ATC H05BX04 (etelcalcetide), each read from that country’s own register.
- This record: United Kingdom, from NHS dm+d (United Kingdom)
- 10 of them publish a price we can compare per daily dose
Etelcalcetide · ATC H05BX04
14 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Italyprice
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
NHS dm+d (United Kingdom)- Active substance
- Etelcalcetide
- Manufacturer
- Amgen Ltd
- Country
- United Kingdom (GB)
- ATC code
- H05BX04
- ATC class
- Etelcalcetide
- Defined daily dose
- 2.1 mg, P
- Reimbursed
- Not published by this register
- Source register
- NHS dm+d (United Kingdom)
- Last checked
- September 13, 2026
Packs & prices · 5
- gtin8715131012076
- gtin8715131022914
- gtin08715131022914
- gtin08715131022907
- gtin8715131022907
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
20 interactions on record for etelcalcetide.
Graded by severity as the source publishes them — 19 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Etelcalcetide · interactions on record
20 records
- 19 severe
- 1 moderate
Most severe, free to view
- FurosemideC03CA01severe
- BumetanideC03CA02severe
- TorasemideC03CA04severe
- Etacrynic acidC03CC01severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Etelcalcetide in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaPARSABIVAmgen Europe B.V., Breda
- SpainPARSABIV 5 MG SOLUCION INYECTABLEAmgen Europe B.V.
- BelgiumParsabiv 5 mgAmgen Europe
- IcelandParsabivAmgen Europe B.V.*
- PolandParsabivAmgen Europe B.V.
- SwedenParsabiv 5 mg Injektionsvätska, lösningAmgen Europe B.V.
- SwitzerlandParsabiv 10.0 mg, InjektionslösungAmgen Switzerland AG
- FinlandParsabivAmgen Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Parsabiv
- Norway · Parsabiv
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of NHS dm+d (United Kingdom). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c0395850-4133-4534-a31c-2db33837574d GET /v1/drugs/c0395850-4133-4534-a31c-2db33837574d?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"apid": "34486911000001104",
"desc": "Parsabiv 5mg/1ml solution for injection vials (Amgen Ltd)",
"form": "Solution for injection",
"vpid": "34486711000001101",
"source": "dmd",
"vtm_id": "775852001",
"strength": "5 mg",
"substance": "Etelcalcetide",
"ingredient": "Etelcalcetide hydrochloride",
"supplier_code": "3303701000001100"
}See everything about etelcalcetide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.